Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Accured Expenses (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Change in Accured Expenses readings, the most recent being $5.4 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 435.54% to $5.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.7 million, a 699.64% increase, with the full-year FY2025 number at $6.7 million, up 699.64% from a year prior.
  • Change in Accured Expenses hit $5.4 million in Q4 2025 for Avalo Therapeutics, up from $1.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.4 million in Q4 2025 to a low of -$4.9 million in Q1 2023.
  • Median Change in Accured Expenses over the past 5 years was -$587000.0 (2022), compared with a mean of -$193950.0.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 1314.08% in 2021 and later crashed 726.21% in 2023.
  • Avalo Therapeutics' Change in Accured Expenses stood at $646000.0 in 2021, then tumbled by 175.54% to -$488000.0 in 2022, then tumbled by 96.72% to -$960000.0 in 2023, then surged by 204.06% to $999000.0 in 2024, then skyrocketed by 435.54% to $5.4 million in 2025.
  • The last three reported values for Change in Accured Expenses were $5.4 million (Q4 2025), $1.0 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.